Review

jurkat t cells (Purdue University Cytometry)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Purdue University Cytometry jurkat t cells

a. <t>Jurkat</t> <t>T</t> cell proliferation following treatment with EVs derived from NSCLC cell lines (A549, HCC827, and H358) at 5, 10, and 20 µg for 96 hr. Proliferation was normalized to PBS-treated Jurkat T cells (dashed line) (mean ± SD, two-way ANOVA with Dunnett’s multiple comparisons test; n=4). b. Left: Representative flow cytometry dot plot showing % cells positive for propidium iodide staining (necrosis marker) in Jurkat T cells treated with 25 µg of H358 EVs or PBS. Right: Representative histogram of CD69 expression (activation marker) under the same conditions. Mean values indicated above the histogram. c. Top: Representative histograms of eFluor™ 450 dye dilution in primary human CD3+, CD3+CD4+, and CD3+CD8+ T cells following treatment with H358 EVs for 96 hr at indicated doses. Reduced dye intensity indicated increased proliferation. Unactivated T cells and volume-matched PBS-treated T cells served as negative and positive controls, respectively. Full gating strategy shown in Fig. S6a. Bottom: Quantification of proliferating T cells (cells left of dashed line) expressed as a percentage relative to PBS control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=6). Primary T cells from a single donor treated with six different H358 EV preps. d. Representative images of human bronchial epithelial cells treated with A549 or H358 EVs (7.5 and 15 µg; 96 hr) compared with PBS control. Bottom: Quantification of cell number normalized to PBS-treated control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=3).

Jurkat T Cells, supplied by Purdue University Cytometry, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jurkat+t+cells/bio_rxiv__64898__2026__05__13__719612-135-15-24?v=Purdue+University+Cytometry
Average 86 stars, based on 1 article reviews

jurkat t cells - by Bioz Stars, 2026-07

86/100 stars

Images

1) Product Images from "Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer"

Article Title: Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer

Journal: bioRxiv

doi: 10.64898/2026.05.13.719612

a. Jurkat T cell proliferation following treatment with EVs derived from NSCLC cell lines (A549, HCC827, and H358) at 5, 10, and 20 µg for 96 hr. Proliferation was normalized to PBS-treated Jurkat T cells (dashed line) (mean ± SD, two-way ANOVA with Dunnett’s multiple comparisons test; n=4). b. Left: Representative flow cytometry dot plot showing % cells positive for propidium iodide staining (necrosis marker) in Jurkat T cells treated with 25 µg of H358 EVs or PBS. Right: Representative histogram of CD69 expression (activation marker) under the same conditions. Mean values indicated above the histogram. c. Top: Representative histograms of eFluor™ 450 dye dilution in primary human CD3+, CD3+CD4+, and CD3+CD8+ T cells following treatment with H358 EVs for 96 hr at indicated doses. Reduced dye intensity indicated increased proliferation. Unactivated T cells and volume-matched PBS-treated T cells served as negative and positive controls, respectively. Full gating strategy shown in Fig. S6a. Bottom: Quantification of proliferating T cells (cells left of dashed line) expressed as a percentage relative to PBS control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=6). Primary T cells from a single donor treated with six different H358 EV preps. d. Representative images of human bronchial epithelial cells treated with A549 or H358 EVs (7.5 and 15 µg; 96 hr) compared with PBS control. Bottom: Quantification of cell number normalized to PBS-treated control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=3).

Figure Legend Snippet: a. Jurkat T cell proliferation following treatment with EVs derived from NSCLC cell lines (A549, HCC827, and H358) at 5, 10, and 20 µg for 96 hr. Proliferation was normalized to PBS-treated Jurkat T cells (dashed line) (mean ± SD, two-way ANOVA with Dunnett’s multiple comparisons test; n=4). b. Left: Representative flow cytometry dot plot showing % cells positive for propidium iodide staining (necrosis marker) in Jurkat T cells treated with 25 µg of H358 EVs or PBS. Right: Representative histogram of CD69 expression (activation marker) under the same conditions. Mean values indicated above the histogram. c. Top: Representative histograms of eFluor™ 450 dye dilution in primary human CD3+, CD3+CD4+, and CD3+CD8+ T cells following treatment with H358 EVs for 96 hr at indicated doses. Reduced dye intensity indicated increased proliferation. Unactivated T cells and volume-matched PBS-treated T cells served as negative and positive controls, respectively. Full gating strategy shown in Fig. S6a. Bottom: Quantification of proliferating T cells (cells left of dashed line) expressed as a percentage relative to PBS control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=6). Primary T cells from a single donor treated with six different H358 EV preps. d. Representative images of human bronchial epithelial cells treated with A549 or H358 EVs (7.5 and 15 µg; 96 hr) compared with PBS control. Bottom: Quantification of cell number normalized to PBS-treated control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=3).

Techniques Used: Derivative Assay, Flow Cytometry, Staining, Marker, Expressing, Activation Assay, Control

$a. Representative immunoblot showing canonical EV markers CD81 and CD63 in H358 EV lysate (5 µg total protein) compared to H358 whole-cell lysate (5 and 25 µg). GAPDH confirms minimal cellular contamination of isolated EVs. b. Immunoblot of pull-down (PD) and flow-through (FT) fractions following CD81- and CD63-immunoprecipitation of H358 EVs. IgG immunoprecipitation served as a control. c. Jurkat T cell proliferation following treatment with total H358 EVs or EVs depleted of CD81+ or CD63+ vesicles (96 hr). EV input was normalized to 5 µg total protein. Proliferation was quantified by eFluor™ 450 dye dilution (mean ± SD; unpaired t-test; n=3). d. Schematic illustrating Brefeldin A (BFA) treatment to inhibit Golgi trafficking and assess its effect on EV secretion. e. Quantification of EV secretion from A549 and H358 cells following 48 hr treatment with BFA (8 ng/mL). EV number is shown per 10 cells. Untreated cells served as a control (mean ± SD; unpaired t-test; n=3). f. Jurkat T cell proliferation following treatment with equal volumes of EVs derived from untreated or BFA-treated H358 cells. Proliferation was normalized to PBS-treated Jurkat T cells (mean ± SD; unpaired t-test; n=4). g. Immunoblot showing expression of the trans-Golgi marker TGOLN2 and canonical EV markers in EV lysates (10 µg total protein) from HCC827, A549, and H358 cells. h. Immunoblot of PD and FT fractions following TGOLN2 or CD81 immunoprecipitation of H358 EVs. IgG immunoprecipitation served as a control. i. Top: Representative histogram of primary human T cell proliferation following treatment with total H358 EVs or EVs depleted of CD81+ or CD63+ vesicles (96 hr), assessed by eFluor™ 450 dye dilution. Bottom: Quantification of proliferating T cells (cells left of dashed line) relative to PBS-treated controls (mean ± SD; one-way ANOVA with Dunnett’s post hoc, n=6). j. Immunoblot of TGOLN2 in EV and whole-cell lysates from TGOLN2-overexpressing A549 cells (A549-TGOLN2) and parent A549 cells. CD81 and GAPDH confirm EV enrichment and purity. k. Jurkat T cell proliferation following treatment with equal numbers of EVs from parental A549 or A549-TGOLN2 cells. Proliferation normalized to PBS-treated controls (mean ± SD; unpaired t-test; n=4). l. Immunoblot of PD and FT fractions following TGOLN2-immunoprecipitation of EVs derived from A549-TGOLN2 cells. CD9 is shown as a canonical EV marker. IgG served as a control. m. Jurkat T cell proliferation following treatment with total A549-TGOLN2 EVs, mock-depleted EVs (IgG), or TGOLN2-depleted EVs (96 hr; 10 and 25 µL input volumes). Proliferation normalized to PBS-treated Jurkat T cells (mean ± SD; unpaired t-test; n=4). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001$
Figure Legend Snippet: a. Representative immunoblot showing canonical EV markers CD81 and CD63 in H358 EV lysate (5 µg total protein) compared to H358 whole-cell lysate (5 and 25 µg). GAPDH confirms minimal cellular contamination of isolated EVs. b. Immunoblot of pull-down (PD) and flow-through (FT) fractions following CD81- and CD63-immunoprecipitation of H358 EVs. IgG immunoprecipitation served as a control. c. Jurkat T cell proliferation following treatment with total H358 EVs or EVs depleted of CD81+ or CD63+ vesicles (96 hr). EV input was normalized to 5 µg total protein. Proliferation was quantified by eFluor™ 450 dye dilution (mean ± SD; unpaired t-test; n=3). d. Schematic illustrating Brefeldin A (BFA) treatment to inhibit Golgi trafficking and assess its effect on EV secretion. e. Quantification of EV secretion from A549 and H358 cells following 48 hr treatment with BFA (8 ng/mL). EV number is shown per 10 cells. Untreated cells served as a control (mean ± SD; unpaired t-test; n=3). f. Jurkat T cell proliferation following treatment with equal volumes of EVs derived from untreated or BFA-treated H358 cells. Proliferation was normalized to PBS-treated Jurkat T cells (mean ± SD; unpaired t-test; n=4). g. Immunoblot showing expression of the trans-Golgi marker TGOLN2 and canonical EV markers in EV lysates (10 µg total protein) from HCC827, A549, and H358 cells. h. Immunoblot of PD and FT fractions following TGOLN2 or CD81 immunoprecipitation of H358 EVs. IgG immunoprecipitation served as a control. i. Top: Representative histogram of primary human T cell proliferation following treatment with total H358 EVs or EVs depleted of CD81+ or CD63+ vesicles (96 hr), assessed by eFluor™ 450 dye dilution. Bottom: Quantification of proliferating T cells (cells left of dashed line) relative to PBS-treated controls (mean ± SD; one-way ANOVA with Dunnett’s post hoc, n=6). j. Immunoblot of TGOLN2 in EV and whole-cell lysates from TGOLN2-overexpressing A549 cells (A549-TGOLN2) and parent A549 cells. CD81 and GAPDH confirm EV enrichment and purity. k. Jurkat T cell proliferation following treatment with equal numbers of EVs from parental A549 or A549-TGOLN2 cells. Proliferation normalized to PBS-treated controls (mean ± SD; unpaired t-test; n=4). l. Immunoblot of PD and FT fractions following TGOLN2-immunoprecipitation of EVs derived from A549-TGOLN2 cells. CD9 is shown as a canonical EV marker. IgG served as a control. m. Jurkat T cell proliferation following treatment with total A549-TGOLN2 EVs, mock-depleted EVs (IgG), or TGOLN2-depleted EVs (96 hr; 10 and 25 µL input volumes). Proliferation normalized to PBS-treated Jurkat T cells (mean ± SD; unpaired t-test; n=4). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

Techniques Used: Western Blot, Isolation, Immunoprecipitation, Control, Derivative Assay, Expressing, Marker

Image Search Results

BUD23 knockdown suppresses the proliferative and migration of NSCLC cells. (A) RT-qPCR was used to quantify BUD23 mRNA levels in HBE cells and a panel of NSCLC cell lines. Validation of BUD23 knockdown efficiency in (B) A549 and (C) H1299 cells by RT-qPCR. Assessment of cell viability in (D) A549 and (E) H1299 cells via CCK-8 assay and cell migration in (F) A549 and (G) H1299 cells by wound healing assay (magnification, ×10). CCK-8 assays of (H) A549 and (I) H1299 cells 24 h after BUD23 knockdown with or without subsequent co-culture with Jurkat T cells for 48 h in Transwell chambers. (J) Quantification of apoptosis in A549 and H1299 cells via Annexin V/PI flow cytometry. **P<0.01 and ***P<0.001 vs. HBE, NC, Con or as indicated. NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative PCR; HBE, human bronchial epithelial; CCK-8, Cell Counting Kit-8; NC, negative control; Con, control; Si1/2, small interfering RNA targeting BUD23.

Journal: Oncology Letters

Article Title: BUD23 is associated with malignancy and correlates with immune infiltration in NSCLC

doi: 10.3892/ol.2026.15608

Figure Lengend Snippet: BUD23 knockdown suppresses the proliferative and migration of NSCLC cells. (A) RT-qPCR was used to quantify BUD23 mRNA levels in HBE cells and a panel of NSCLC cell lines. Validation of BUD23 knockdown efficiency in (B) A549 and (C) H1299 cells by RT-qPCR. Assessment of cell viability in (D) A549 and (E) H1299 cells via CCK-8 assay and cell migration in (F) A549 and (G) H1299 cells by wound healing assay (magnification, ×10). CCK-8 assays of (H) A549 and (I) H1299 cells 24 h after BUD23 knockdown with or without subsequent co-culture with Jurkat T cells for 48 h in Transwell chambers. (J) Quantification of apoptosis in A549 and H1299 cells via Annexin V/PI flow cytometry. **P<0.01 and ***P<0.001 vs. HBE, NC, Con or as indicated. NSCLC, non-small cell lung cancer; RT-qPCR, reverse transcription-quantitative PCR; HBE, human bronchial epithelial; CCK-8, Cell Counting Kit-8; NC, negative control; Con, control; Si1/2, small interfering RNA targeting BUD23.

Article Snippet: The HBE [full name: HBE4-E6/E7 (Human Bronchial Epithelial Cells; cat. no. CRL-2078)] cell line, A549 lung adenocarcinoma cell line (cat. no. CCL-185), H1299 lung large cell carcinoma cell line (cat. no. CRL-5803), H460 lung large cell carcinoma cell line (cat. no. HTB-177) and Jurkat T cells (cat. no. TIB-152; a childhood T acute lymphoblastic leukemia T-cell line), were purchased from the American Type Culture Collection.

Techniques: Knockdown, Migration, Quantitative RT-PCR, Biomarker Discovery, CCK-8 Assay, Wound Healing Assay, Co-Culture Assay, Flow Cytometry, Reverse Transcription, Real-time Polymerase Chain Reaction, Cell Counting, Negative Control, Control, Small Interfering RNA

Journal: bioRxiv

Article Title: Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer

doi: 10.64898/2026.05.13.719612

Figure Lengend Snippet: a. Jurkat T cell proliferation following treatment with EVs derived from NSCLC cell lines (A549, HCC827, and H358) at 5, 10, and 20 µg for 96 hr. Proliferation was normalized to PBS-treated Jurkat T cells (dashed line) (mean ± SD, two-way ANOVA with Dunnett’s multiple comparisons test; n=4). b. Left: Representative flow cytometry dot plot showing % cells positive for propidium iodide staining (necrosis marker) in Jurkat T cells treated with 25 µg of H358 EVs or PBS. Right: Representative histogram of CD69 expression (activation marker) under the same conditions. Mean values indicated above the histogram. c. Top: Representative histograms of eFluor™ 450 dye dilution in primary human CD3+, CD3+CD4+, and CD3+CD8+ T cells following treatment with H358 EVs for 96 hr at indicated doses. Reduced dye intensity indicated increased proliferation. Unactivated T cells and volume-matched PBS-treated T cells served as negative and positive controls, respectively. Full gating strategy shown in Fig. S6a. Bottom: Quantification of proliferating T cells (cells left of dashed line) expressed as a percentage relative to PBS control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=6). Primary T cells from a single donor treated with six different H358 EV preps. d. Representative images of human bronchial epithelial cells treated with A549 or H358 EVs (7.5 and 15 µg; 96 hr) compared with PBS control. Bottom: Quantification of cell number normalized to PBS-treated control (mean ± SD, one-way ANOVA with Dunnett’s multiple comparisons test; n=3).

Article Snippet: A549 (CCL-185TM, RRID:CVCL_0023), HCC827 (CRL-2868TM, RRID:CVCL_2063) and H358 (CRL-5807TM, RRID:CVCL_1559) were purchased from ATCC, and Jurkat T cells (RRID:CVCL_0065) were provided by Dr. Kazemian (Purdue University).

Techniques: Derivative Assay, Flow Cytometry, Staining, Marker, Expressing, Activation Assay, Control

Journal: bioRxiv

Article Title: Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer

doi: 10.64898/2026.05.13.719612

Figure Lengend Snippet: a. Representative immunoblot showing canonical EV markers CD81 and CD63 in H358 EV lysate (5 µg total protein) compared to H358 whole-cell lysate (5 and 25 µg). GAPDH confirms minimal cellular contamination of isolated EVs. b. Immunoblot of pull-down (PD) and flow-through (FT) fractions following CD81- and CD63-immunoprecipitation of H358 EVs. IgG immunoprecipitation served as a control. c. Jurkat T cell proliferation following treatment with total H358 EVs or EVs depleted of CD81+ or CD63+ vesicles (96 hr). EV input was normalized to 5 µg total protein. Proliferation was quantified by eFluor™ 450 dye dilution (mean ± SD; unpaired t-test; n=3). d. Schematic illustrating Brefeldin A (BFA) treatment to inhibit Golgi trafficking and assess its effect on EV secretion. e. Quantification of EV secretion from A549 and H358 cells following 48 hr treatment with BFA (8 ng/mL). EV number is shown per 10 cells. Untreated cells served as a control (mean ± SD; unpaired t-test; n=3). f. Jurkat T cell proliferation following treatment with equal volumes of EVs derived from untreated or BFA-treated H358 cells. Proliferation was normalized to PBS-treated Jurkat T cells (mean ± SD; unpaired t-test; n=4). g. Immunoblot showing expression of the trans-Golgi marker TGOLN2 and canonical EV markers in EV lysates (10 µg total protein) from HCC827, A549, and H358 cells. h. Immunoblot of PD and FT fractions following TGOLN2 or CD81 immunoprecipitation of H358 EVs. IgG immunoprecipitation served as a control. i. Top: Representative histogram of primary human T cell proliferation following treatment with total H358 EVs or EVs depleted of CD81+ or CD63+ vesicles (96 hr), assessed by eFluor™ 450 dye dilution. Bottom: Quantification of proliferating T cells (cells left of dashed line) relative to PBS-treated controls (mean ± SD; one-way ANOVA with Dunnett’s post hoc, n=6). j. Immunoblot of TGOLN2 in EV and whole-cell lysates from TGOLN2-overexpressing A549 cells (A549-TGOLN2) and parent A549 cells. CD81 and GAPDH confirm EV enrichment and purity. k. Jurkat T cell proliferation following treatment with equal numbers of EVs from parental A549 or A549-TGOLN2 cells. Proliferation normalized to PBS-treated controls (mean ± SD; unpaired t-test; n=4). l. Immunoblot of PD and FT fractions following TGOLN2-immunoprecipitation of EVs derived from A549-TGOLN2 cells. CD9 is shown as a canonical EV marker. IgG served as a control. m. Jurkat T cell proliferation following treatment with total A549-TGOLN2 EVs, mock-depleted EVs (IgG), or TGOLN2-depleted EVs (96 hr; 10 and 25 µL input volumes). Proliferation normalized to PBS-treated Jurkat T cells (mean ± SD; unpaired t-test; n=4). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

Techniques: Western Blot, Isolation, Immunoprecipitation, Control, Derivative Assay, Expressing, Marker

Outputs of capacitance measurements for a T cell (Jurkat) bolus fed process. Panel (A) overlays the online capacitance trace for the LBB process with the viable and total cell concentrations. Feed points have also been marked on the figure. Panel (B) reproduces the lag phase data (the highlighted region in A) for the run to demonstrate the probe's ability to produce correlative results well below the typically observed operational ranges of the probes seen in current biotechnology processes. Panel (C) is a bubble‐plot of viable cell concentration versus capacitance which displays cell diameter and overall culture viability.

Journal: Biotechnology Journal

Article Title: Capacitance Technology Enables Automated Feeding, Improved Expansion, and Higher Throughput of CAR‐T Cell Stirred‐Tank Bioreactor Cultures

doi: 10.1002/biot.70226

Figure Lengend Snippet: Outputs of capacitance measurements for a T cell (Jurkat) bolus fed process. Panel (A) overlays the online capacitance trace for the LBB process with the viable and total cell concentrations. Feed points have also been marked on the figure. Panel (B) reproduces the lag phase data (the highlighted region in A) for the run to demonstrate the probe's ability to produce correlative results well below the typically observed operational ranges of the probes seen in current biotechnology processes. Panel (C) is a bubble‐plot of viable cell concentration versus capacitance which displays cell diameter and overall culture viability.

Article Snippet: T Cell (Jurkat) batch , Eppendorf 2L glass vessel , Futura , Batch (1.2L).

Techniques: Concentration Assay

Summary data for various feeding regimes employed in T cell (Jurkat) cultures. Panel (A) summarizes the different feeding regimes with respect to process time used for the various Jurkat runs. Panels B‐F all present the graphs of sample time recorded capacitance, viable cell number and culture volume (for ease of understanding feeding implications). Feed zones are marked by the shaded region and relevant detail given in magenta text. Panel (B) = batch process; Panel (C) = LBB; Panel (D) = capacitance‐based bolus; Panel (E) = linear feed; Panel (F) = exponential Feed.

Journal: Biotechnology Journal

Article Title: Capacitance Technology Enables Automated Feeding, Improved Expansion, and Higher Throughput of CAR‐T Cell Stirred‐Tank Bioreactor Cultures

doi: 10.1002/biot.70226

Figure Lengend Snippet: Summary data for various feeding regimes employed in T cell (Jurkat) cultures. Panel (A) summarizes the different feeding regimes with respect to process time used for the various Jurkat runs. Panels B‐F all present the graphs of sample time recorded capacitance, viable cell number and culture volume (for ease of understanding feeding implications). Feed zones are marked by the shaded region and relevant detail given in magenta text. Panel (B) = batch process; Panel (C) = LBB; Panel (D) = capacitance‐based bolus; Panel (E) = linear feed; Panel (F) = exponential Feed.

Article Snippet: T Cell (Jurkat) batch , Eppendorf 2L glass vessel , Futura , Batch (1.2L).

Techniques:

Summary data for the different feed regime processes for T cells (Jurkat). Panel (A) gives an overlaid viable cell number graph for the different processes to compare culture time and cell yields obtained across the processes. Panel (B) presents the viability data for the same processes to allow for understanding of where ideal harvest points may occur. Panel (C) contextualizes the harvest point yields (selected as last point of ideal viability) in terms of largest doses of Kymriah for the treatment of either ALL or B‐cell lymphoma.

Journal: Biotechnology Journal

Article Title: Capacitance Technology Enables Automated Feeding, Improved Expansion, and Higher Throughput of CAR‐T Cell Stirred‐Tank Bioreactor Cultures

doi: 10.1002/biot.70226

Figure Lengend Snippet: Summary data for the different feed regime processes for T cells (Jurkat). Panel (A) gives an overlaid viable cell number graph for the different processes to compare culture time and cell yields obtained across the processes. Panel (B) presents the viability data for the same processes to allow for understanding of where ideal harvest points may occur. Panel (C) contextualizes the harvest point yields (selected as last point of ideal viability) in terms of largest doses of Kymriah for the treatment of either ALL or B‐cell lymphoma.

Article Snippet: T Cell (Jurkat) batch , Eppendorf 2L glass vessel , Futura , Batch (1.2L).

Techniques:

Review

Structured Review

Images

1) Product Images from "Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer"

Similar Products

Image Search Results